Biotech Startups

VivantX works in precision oncology, applying tumour molecular profiling and personalized therapeutics to cancer care. The company draws on advisors in medical and clinical oncology, data science, and digital health.

1 investor

Vivasure Medical develops polymer-based vascular closure devices and delivery systems for structural heart and endovascular interventions. The company operates an ISO 13485 certified manufacturing facility in Ireland and was acquired by Haemonetics Corporation in January 2026.

1 investor

VIVEbiotech is a contract development and manufacturing organization (CDMO) specialized exclusively in lentiviral vectors for both ex vivo and in vivo administration, following EMA and FDA regulatory requirements. It serves biotech and pharmaceutical companies across the US, Europe, Asia, and Australia.

1 investor

Vivere is an early-stage biotech developing cancer therapies that use a bioengineering platform (based on UC Berkeley research) to activate the immune system against "cold" solid tumors through targeted delivery. It focuses on immuno-oncology and gene/viral vector engineering to treat difficult solid cancers.

1 investor

VivoBio is a beneficial bacteria product developed for professional greenhouse and indoor growers, applied through irrigation, germination, or foliar spray to increase crop yield and shelf life. The company serves the agricultural sector with microbial solutions that support nutrient uptake, plant establishment, and crop quality.

1 investor

Vivoryon is a biotech company focused on developing therapeutics, with a leadership team experienced in pharmaceutical development, clinical research, and life sciences business operations.

1 investor

Vivtex is a drug development company applying computational science and pre-clinical research to advance new medicines. It operates in the biotech/therapeutics space, working on drug development and related laboratory research.

1 investor

Vizgen develops spatial profiling instruments and reagents for high-throughput analysis of gene expression and protein distribution in tissue samples. The company serves research and diagnostic laboratories in the life sciences and precision oncology fields.

1 investor

Axia breeds and develops tomato and vegetable seeds using advanced techniques with emphasis on quality and respect for people, nature, and the environment. The company serves greenhouse growers worldwide with a focus on superior seed genetics.

1 investor

Volumina Medical develops advanced biomaterial technologies for soft-tissue regeneration and restoration. The company translates scientific discoveries from material science and engineering into minimally invasive medical solutions for clinical use.

1 investor

Voro Therapeutics develops tumor-activated biologics, specifically an antibody-based platform called PrimeBody™, designed to treat cancers including colorectal, gastric, prostate, and lung cancers while minimizing systemic toxicity. The company leverages masking technology and conditionally activated linkers to enable systemic delivery with tumor-specific activation.

1 investor

VPCIR develops non-invasive lateral flow diagnostic test sticks that detect living pathogens in saliva, using patented Rolling Circle Amplification technology for point-of-care Tuberculosis testing. Its pipeline extends to other infectious diseases such as Malaria, targeting affordable, accessible diagnostics for global healthcare.

1 investor

VUGENE offers an AI/ML-powered multi-omics analysis platform that turns raw biological data—genomics, transcriptomics, proteomics, metabolomics, epigenomics, and single-cell data—into actionable insights on how drugs affect biology. It serves principal investigators, research institutions, biotech and pharmaceutical companies, hospitals, and contract research organizations for target identification, mechanism-of-action, and translational research.

1 investor

vVARDIS develops biomimetic, non-invasive dental products based on P11-4 peptide technology to treat early-stage tooth decay by regenerating enamel without drilling. The Swiss company sells chairside solutions to dental professionals, DSOs, and universities.

1 investor

Vyne Therapeutics is a biopharmaceutical company developing treatments for Graves' disease and thyroid eye disease (TED). Its lead candidate is designed to block the interaction of autoantibodies with the TSH receptor to interrupt the disease mechanism.

1 investor

Vysioneer builds AI software that analyzes tumor lesions in medical imaging to assess treatment efficacy, aiming to make oncology clinical trials smaller and faster. It serves cancer researchers and drug developers by extracting all-lesion features and biomarkers that predict treatment outcomes.

1 investor

Vytala develops a plant-based medical food using its Lym-X-Sorb lipid technology to improve absorption of dietary fat, choline, and essential fatty acids in patients with fat malabsorption from conditions such as cystic fibrosis and pancreatic insufficiency. The product aims to reduce GI symptoms and support weight, growth, and nutrient status without complex diets or medications, and is reimbursable through CMS.

1 investor

Vytrus is a biotechnology company focused on plant-based science and product development. The company develops formulations and products leveraging botanical expertise for commercial applications.

1 investor

Wake offers medicinal and psychedelic fungi therapy combined with genomics-based integration aimed at supporting human health and personal transformation. It operates in the health and wellness industry.

1 investor

Walder Ventures is a mission-driven investment vehicle established by Joseph and Elizabeth Walder to support programs and organizations benefiting the Chicago region, with a focus on life sciences and sustainability. Its inaugural investment is in Portal Innovations, a Chicago-based incubator for life sciences, medtech, and bioinformatics entrepreneurs.

1 investor

Walking Fish Therapeutics develops cell therapies aimed at restoring health and function in patients. The company is a biotech focused on therapeutic development.

1 investor

BYOHM develops bioelectrochemical systems that extract hydrogen and biomethane from wastewater and organic waste, generating net energy positive treatment with up to 10x more energy output than input. The technology targets municipal and industrial wastewater treatment operators seeking to reduce energy costs and recover valuable fuels.

1 investor

Watchfrog is an independent laboratory specializing in testing for endocrine-disrupting chemicals. It develops and offers alternative testing methods to replace animal studies, serving manufacturers across consumer goods, pharmaceutical, cosmetic, and food industries seeking to evaluate the safety and regulatory compliance of their ingredients, products, and packaging.

1 investor

Watchmaker Genomics develops and manufactures purpose-designed enzymes, reagents, and workflows for molecular biology and genomics applications, including inherited disease, somatic oncology, transcriptomics, and epigenomics research. It operates as an OEM supplier serving genomics technology developers and high-throughput sequencing labs.

1 investor